argenx SE (ARGX) Stock Analysis
Healthcare · Biotechnology
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... Read more
TrendMatrix rates argenx SE (ARGX) as Hold with moderate confidence. The stock trades at $697.05 with +24.3% upside to the $866.41 price target. Overall score: 5.9/10 across 10 analysis dimensions. Reward/risk ratio: 3.1:1.
Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: moderate.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates argenx SE (ARGX) as Hold with moderate confidence. Score 5.9/10.
Take-profit target: $866.41 (+24.3% upside). Reward/risk ratio: 3.1:1. Stop-loss: $641.99.
Negative momentum; Below 200-day MA.
argenx SE trades at a P/E of 34.6 (forward 20.5). TrendMatrix value score: 5.3/10. Verdict: Hold.
25 analysts cover ARGX with a consensus score of 4.2/5. Average price target: $1019.
What does argenx SE do?argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in...
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.